乳腺癌患者化疗致肝损伤1例分析

doi:10.19803/j.1672-8629.2020.10.11

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (10): 703-706.
DOI: 10.19803/j.1672-8629.2020.10.11

乳腺癌患者化疗致肝损伤1例分析

沈丽梦, 姜孙旻, 姚荧, 徐银莹^*

南京医科大学附属无锡妇幼保健院,江苏无锡 214002

收稿日期:2020-10-14 修回日期:2020-10-14 出版日期:2020-10-15 发布日期:2020-10-13
通讯作者: ^*徐银莹,女,本科,主管药师,临床药学。E-mail：xyy657014234@163.com
作者简介:沈丽梦,女,本科,药师,临床药学。
基金资助:
无锡市卫计委科研青年项目（Q201603）; 无锡市卫计委“科教强卫工程”青年医学人才项目（QNRC025）

One Case of Hepatic Injury Caused by Chemotherapy of Breast Cancer

SHEN Limeng, JIANG Sunmin, YAO Ying, XU Yinying^*

The Affiliated Wuxi Matemity and Child Health Care Hospital of Nanjing Medical University, Wuxi Jiangsu 214002, China

Received:2020-10-14 Revised:2020-10-14 Online:2020-10-15 Published:2020-10-13

摘要/Abstract

摘要： 目的对乳腺癌患者化疗出现药物性肝损伤（drug-induced liver injury,DILI）原因分析,为相关领域工作者提供借鉴。方法根据药物性肝损伤诊治指南、相关研究报道及Roussel Uclaf 因果关系评估法（the roussel uclaf causality assessment method,RUCAM）分析本院1例乳腺癌患者多周期化疗后出现肝损伤的原因,评估可能导致肝损伤的药物。结果该患者DILI不能排除,通过用药时间及RUCAM量表进行关联性评价,发现患者的肝损伤与曲妥珠单抗、紫杉醇及西咪替丁存在相关性。结论 DILI是抗肿瘤药物治疗的剂量限制性毒性。对需多周期化疗的恶性肿瘤患者而言,使用RUCAM量表可较好地鉴别可能的DILI,从而提高肿瘤患者治疗效果。

关键词: 乳腺癌, 化疗, 药物性肝损伤, Roussel Vclaf因果关系评估法

Abstract: Objective To analyze the causes of drug-induced liver injury (DILI) in breast cancer patients during chemotherapy, in order to provide reference for workers in related fields. Methods The causes of DILI in a breast cancer patient with multiple chemotherapies were explored and the drugs that may cause liver injury were evaluated according to the guidelines for the diagnosis and treatment of drug-induced liver injury, relevant research publications and the Roussel Uclaf Causality Assessment Method(RUCAM). Results This patient's DILI could not be excluded. Considering length of drug administration and RUCAM quantitative form, the liver injury showed associations with trastuzumab, paclitaxel and cimetidine. Conclusion DILI is a dose-limiting toxicity of anti-tumor drugs. For patients with malignant tumors that require multiple cycles of chemotherapy, RUCAM quantitative form can distinguish potential DILI and improve treatment outcomes.

Key words: breast cancer, chemotherapy, drug-induced liver injury, RUCAM

中图分类号:

R969.2

沈丽梦, 姜孙旻, 姚荧, 徐银莹. 乳腺癌患者化疗致肝损伤1例分析[J]. 中国药物警戒, 2020, 17(10): 703-706.

SHEN Limeng, JIANG Sunmin, YAO Ying, XU Yinying. One Case of Hepatic Injury Caused by Chemotherapy of Breast Cancer[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 703-706.

参考文献

[1] Yu LC, Mao YM, Chen CW.Diagnosis and treatment guideline on drug-induced liver injury[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2015, 23(10):1752-1769.
[2] Jia WP, Guo DH, Tian XY, et al.Analysis of 1110 Cases of Drug- induced Liver Injury in 79 Hospitals[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(8): 481-485.
[3] Yu SY, Yao Y.Expert consensus on prevention and management of Chemotherapy Drug-induced Liver Injury(肿瘤药物相关性肝损伤防治专家共识)[M]. Beijing: Peking Union medical college press, 2014:33-35.
[4] National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [EB/OL]. (2019-09-08) [2018-01-15]. https://www.ncbi.nlm.nih.gov/books/NBK548093/
[5] Ma L, Shi J F, Tong N. Study on adverse reactions of paclitaxel[J]. Chinese Pharmacy(中国药房), 2018, 29(21): 3014-3017.
[6] Weng BW.Comparison between the Weekly and Conventional 3-weekly Taxane-based Chemotherapies in Ovarian Cancers-a Meta- analysis[D]. Shandong: Shandong University, 2015.
[7] Gan G, Gu CJ.Analysis of 73 Adverse Drug Reaction/Event Reports on Liver Damage Induced by Anticancer Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2011, 8(11): 53-56.
[8] Liu YS, Zhao K, Zhang GQ.Analysis of 129 Cases of Adverse Drug Reactions Induced by Paclitaxel Injection in Patients with Breast Cancer in Our Hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(3): 173-175.
[9] Guo XY, Zhang YF, Li XZ.Adverse Reactions of Weekly Paclitaxel Injection Regimen in Postoperative Chemotherapy of Breast Cancer[J]. Chinese Medicine and Clinic(中国药物与临床), 2013, 13(12): 1638-1639.
[10] Ishizuna K, Ninomiya J, Ogawa T, et al.Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report[J]. Journal of Medical Case Reports, 2014, 8(1):417.
[11] Vucicevic D,Carey EJ,Karlin NJ.Trastuzumab-induced hepatotoxicity: a case report.[J] .Breast Care (Basel), 2013, 8(2): 146-8.
[12] Srinivasan S, Parsa V, Liu CY, et al.Trastuzumab-Induced Hepatotoxicity[J]. Annals of Pharmacotherapy, 2008, 42(10): 1497-1501.
[13] Xie R, Zhao N, Cui YM.Trastuzumab-induced hepatotoxicity and analysis of adverse drug reaction: a case Report[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2017, 33(10): 936-938.
[14] Munoz A, Carrera S, Ferreiro J, et al.Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer[J]. Annals of Oncology, 2007, 18(12):2045-2046.
[15] Zhang XL.Analysis of 306 Cases of Cimetidine Adverse Reaction[J]. Guide of China Medicine(中国医药指南), 2014,12(21):72-73.
[16] Tan HF, Wang KR.Analysis of 20 Cases of Adverse Reactions Caused by Cimetidine[J]. China Modern Doctor(中国现代医生), 2008,46(16):100-101.
[17] Wang L, Xu T, Tang Y.Adverse Drug Reaction Induced by Cemetidine: Literature Analysis of 306 Cases[J]. Chinese Pharmacy(中国药房),2008,19(17):1347-1349.
[18] Zhang NQ.Analysis of 36 Cases of Adverse Reactions to Promethazine[J]. Chinese Journal of Rural Medicine and Pharmacy(中国乡村医药), 2012, 19(1): 46-47.
[19] Lun XQ.Analysis of 156 Cases of Adverse Reactions to Promethazine[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2006, 3(3): 135-137.
[20] Cai CJ. Clinical Analysis of 20 Cases of Adverse Reactions to Promethazine Hydrochloride[J]. Journal of Yangtze University (Natural Science Editio)(长江大学学报), 2014, 11(30): 93-93-95.
[21] The U.S. department of health and human services. Common Terminology Criteria for Adverse Events(CTCAE).V5.0.[EB/OL]. (2019-09-08)[2017-11-27]. https://ctep.cancer.gov/protocolde- velopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

乳腺癌患者化疗致肝损伤1例分析

One Case of Hepatic Injury Caused by Chemotherapy of Breast Cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[2]	王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
[3]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[4]	詹姆斯·布坎南. 用 nR 改良海氏法则及 P_ALT 评估药物性肝损伤研究进展[J]. 中国药物警戒, 2024, 21(1): 117-120.
[5]	何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920.
[6]	严亦舒, 赵岩, 卢天公, 孙震晓. 大黄素-8-O-β-D-葡萄糖苷联合紫杉醇抑制人乳腺癌细胞活力及侵袭转移的研究[J]. 中国药物警戒, 2023, 20(7): 728-734.
[7]	陈崇泽, 李婕, 旷煉, 檀学文, 刘敏惠, 刘熙, 郑燕钗, 靳洪涛. 448例住院患者药物性肝损伤相关不良反应特征分析[J]. 中国药物警戒, 2023, 20(6): 697-704.
[8]	罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504.
[9]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[10]	姚克宇, 张舒琪, 金锐, 刘丽红, 朱彦. 药物致肝损伤数据集的比较研究[J]. 中国药物警戒, 2023, 20(5): 568-573.
[11]	陈超, 朱兰, 刘丽红, 韩佳寅, 朱彦. 文献来源的补骨脂及其制剂引起药物性肝损伤特点探析[J]. 中国药物警戒, 2023, 20(4): 449-453.
[12]	焦福智, 陈雅蕊, 姬薇, 郝建朋, 关泉林. PD-1抑制剂联合化疗一线新辅助治疗局部进展期胃腺癌的近期疗效及安全性评估[J]. 中国药物警戒, 2023, 20(3): 301-305.
[13]	王宇, 黄婧怡, 侯立新, 李爽, 崔永康, 黄兰蔚. 社区获得性肺炎患者抗生素相关性肝损伤外周血体液免疫特点分析[J]. 中国药物警戒, 2023, 20(2): 132-135.
[14]	于洁, 朱浩翔, 张继明. 疑似千里光类药物致药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 136-139.
[15]	李晓娟, 张爱武, 魏颖. 伤风停胶囊致急性药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 213-214.